Strategies to overcome therapeutic resistance in renal cell carcinoma
- 1 March 2017
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 35 (3) , 102-110
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Emerging immunotherapies for renal cell carcinomaAnnals of Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2Journal of Biological Chemistry, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971